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Two prospective, randomized studies evaluated
everolimus 1.5 vs. 3 mg/day with steroids and low-
exposure cyclosporine (CsA) (C2 monitoring) in de
novo renal transplant patients. Everolimus dosing
was adjusted to maintain a minimum trough level of
3 ng/mL. Study 1 (A2306; n = 237) had no induction
therapy; in Study 2 (A2307; n = 256) basiliximab was
administered (Days 0 and 4). The primary endpoint was
renal function at 6 months. CsA C2 target levels, ini-
tially 1200 ng/mL in Study 1 and 600 ng/mL in Study
2, were tapered over time post-transplant. Median cre-
atinine levels in Study 1 were 133 and 132 lmol/L at 6
months in the 1.5 and 3 mg/day groups, respectively,
and 130 lmol/L in both groups in Study 2. Biopsy-
proven acute rejection (BPAR) occurred in 25.0% and
15.2% of patients in the 1.5 and 3 mg/day groups in
Study 1, and 13.7% and 15.1% in Study 2. Incidence
of BPAR was significantly higher in patients with an
everolimus trough < 3 ng/mL. There were no signifi-
cant between-group differences in the composite end-
point of BPAR, graft loss or death, nor any significant
between-group differences in adverse events in either
study. Concentration-controlled everolimus with low-
exposure CsA provided effective protection against re-
jection with good renal function.
Key words: Cyclosporine, everolimus, immunosup-
pressive regimen, renal function, therapeutic drug
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Introduction
With 1-year renal graft survival rates now exceeding 90%
(1), the new clinical challenge is to develop immunosup-
pressive regimens that minimize the risk of long-term graft
loss while preserving current low rates of acute rejection.
Renal function is thought to be a predictor of long-term
renal allograft survival (2), and the introduction of new im-
munosuppressive drugs offers the opportunity to assess
regimens that may reduce renal toxicity without impair-
ing efficacy. In view of the known nephrotoxic potential of
calcineurin inhibitors (CNIs), CNI-sparing regimens are an
attractive option. Proliferation signal inhibitors are potent
immunosuppressants that appear to be non-nephrotoxic
(3), suggesting that use of a proliferation signal inhibitor
with a CNI may permit CNI dose reduction without loss
of immunosuppressive potency or increased renal toxicity,
and thus provide a valuable therapeutic option.
The novel immunosuppressant everolimus (Certican®,
RAD, Novartis Pharma AG, Basel, Switzerland) inhibits
the T-lymphocyte proliferative response to cytokine
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signals (4), thus complementing the inhibitory effect of cy-
closporine (CsA) on T-cell-dependent growth factors such
as interleukin (IL)-2 (5,6). In vitro and preclinical evidence
has demonstrated that everolimus enhances the immuno-
suppressive action of CsA-based regimens (7–10), and
Phase III trials in which everolimus was used in combi-
nation with full-dose CsA have shown equivalent efficacy
to mycophenolate mofetil (MMF) (11,12).
An open-label pilot study conducted in 111 de novo re-
nal transplant patients receiving everolimus compared
outcomes using full-dose or low-dose CsA (13). In patients
receiving low-dose CsA, the incidence of biopsy-proven
acute rejection (BPAR) at 12 months was 7%. Importantly,
serum creatinine levels were consistently lower than in the
full-dose CsA group, suggesting that use of a proliferation
signal inhibitor with low-dose CsA may be an effective im-
munosuppressive strategy.
In the light of the findings from this pilot study, two
prospective, multicenter, randomized studies were set
up to evaluate the efficacy and safety of two doses of
everolimus (1.5 mg/day vs. 3 mg/day) in combination with
low-exposure CsA and corticosteroids in de novo renal
transplant recipients. Given the equivalent efficacy demon-
strated vs. MMF in Phase III trials, no comparator arm was
included. An open-label design was adopted as therapeutic
drug monitoring required investigators to adjust the dose
of everolimus.
The two studies were undertaken concurrently, with sim-
ilar protocols other than variations in CsA exposure levels
and use of an IL-2 receptor antagonist in one of the trials.
The methodologies and results of the two trials, A2306




Two prospective, parallel-group, open-label studies were undertaken to
compare the safety and efficacy of two doses of everolimus used in combi-
nation with optimized CsA administration and corticosteroids. The designs
were based on previous trials of everolimus in combination with CsA (11–
13). In Study 1 [based on two Phase III studies with full-dose CsA compar-
ing everolimus with MMF (11,12)], no induction therapy was employed. In
Study 2 [based on a pilot Phase II study with everolimus in combination with
an IL-2 receptor antagonist comparing full- and reduced-dose CsA (13)], the
IL-2 receptor antagonist, basiliximab, was administered and CsA exposure
targets were, accordingly, lower than in Study 1 (see ‘Immunosuppression’
below). In all other respects the two studies followed similar protocols. Lo-
cal medical ethics committees approved the protocols and the studies were
performed in accordance with the Declaration of Helsinki and US Food and
Drug Administration guidelines for good clinical practice.
Inclusion and exclusion criteria
Adult male or nonpregnant female patients undergoing primary cadav-
eric, living-unrelated or human leukocyte antigen-mismatched living-related
donor kidney transplantation were enrolled and received treatment for up
to 1 year. In Study 1, but not in Study 2, patients had to have a functional
graft within 24 h. All patients gave written informed consent.
Immunosuppression
Patients were randomized to either 1.5 mg/day or 3 mg/day everolimus, and
treatment with all agents was initiated, within 24 h of transplantation. All
nonblack patients were randomized to receive 1.5 or 3 mg/day everolimus.
As black patients have a higher everolimus clearance rate than Caucasian
patients (14), all black subjects received 3 mg/day everolimus to minimize
the risk of graft loss. Everolimus was administered twice daily at 12-hourly
intervals, simultaneously with CsA, at either 0.75 mg b.i.d. or 1.5 mg b.i.d.
Everolimus trough concentrations were measured on Days 5, 7, 14 and
28 and at Months 2, 3, 4 and 6. A minimum target trough level of 3 ng/mL
was adopted based on the results of a previous exposure-response analysis
(15). Dose was adjusted by 0.5 mg or 0.75 mg b.i.d. if trough concentration
was less than 3 ng/mL, and trough concentration was measured 5 days
after dose adjustment to ensure the target was achieved. The dose was
reduced if patients could not tolerate full-dose everolimus and discontinued
if necessary.
CsA (Neoral®, Novartis Pharma AG, Basel, Switzerland) was given twice
daily in equal divided doses at 12-h intervals, at an initial dose of 8 mg/kg/day
in Study 1 and 4 mg/kg/day in Study 2. Adjustment of CsA dose to target
levels, optimized on the basis of pharmacokinetic and pharmacodynamic, ef-
ficacy and safety data from previous studies (11–13), was achieved through
monitoring of CsA concentration 2 h after dosing (C2). C2 is a superior marker
of CsA exposure and hence predictor of acute rejection than trough con-
centration (16–18). Blood CsA (C2) was measured in whole blood taken 2 h
(±10 min) after the morning dose on Days 3, 5, 7, 14 and 28 and at Months
2, 3, 4 and 6. CsA dose was adjusted from Day 3 to target C2 ranges that
were tapered over time post-transplant. In Study 1, target C2 was 1200
ng/mL (range 1000–1400 ng/mL) for Weeks 0–4; 800 ng/mL (range 700–
900 ng/mL) for Weeks 5–8; 600 ng/mL (range 550–650 ng/mL) for Weeks
9–12; and 400 ng/mL (range 350–450 ng/mL) for Months 4–12. In Study
2, in which patients also received basiliximab, target C2 was set lower:
600 ng/mL (500–700 ng/mL) for Weeks 0–8 and 400 ng/mL (range 350–
450 ng/mL) from Week 9 to Month 12. CsA exposure could be reduced
in the presence of delayed graft function, if patients received antibodies
for steroid-resistant rejection episodes or vascular rejection, or for drug-
induced kidney dysfunction. To provide additional information, CsA trough
concentrations were measured in samples taken immediately before the
morning dose on Days 5,7,14 and 28, and at study visits for Months 2, 3, 4
and 6; these values were not used to adjust CsA dose.
Intravenous corticosteroid was given according to local practice. Oral pred-
nisone was initiated on Day 1 at a minimum dose of 20 mg/day and con-
tinued for at least 12 months. The dose was reduced according to local
practice to a minimum of 5 mg/day. In Study 2, basiliximab was given ac-
cording to the standard dose regimen, 20 mg on Day 0 (within 2 h before
transplantation) and Day 4 as an i.v. bolus.
Primary endpoint
The primary endpoint was renal function, measured by calculated glomeru-
lar filtration rate (GFR) (Nankivell formula) (19) and calculated creatinine clear-
ance (Cockroft-Gault) (20) or serum creatinine at 6 months.
Secondary endpoints
Efficacy endpoints included the incidence of efficacy failure (first occurrence
of either BPAR, graft loss, death or lost to follow-up), graft loss, death and
BPAR. All suspected acute rejection episodes were recorded. A graft core
biopsy performed within 48 h of suspected rejection was graded according
to the 1997 Banff criteria (21).
All adverse events, infections and serious adverse events were recorded.
Laboratory values were determined on Days 7, 14 and 28 and Months 2, 3,
4 and 6 and all data assessed in a central laboratory.
Statistical methods
Data were analyzed separately for each study. All summary statistics are pre-
sented by treatment group. All statistical tests were two-sided and used the
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0.05 level of significance. Safety and tolerability analyses were performed
on the safety populations in each study, defined as all patients who received
at least one dose of study medication and underwent at least one safety
assessment. Safety evaluations were made to Day 225.
Renal function data to Month 6 were analysed using all data, including those
observed after discontinuation of study medication [intent-to-treat (ITT) anal-
ysis], and were compared between treatment groups using a two-sided
Wilcoxon rank-sum test. Patients with graft loss were excluded from the
renal function analyses from the day on which the graft was lost.
Efficacy analyses were conducted on the ITT population using all efficacy
data to Day 194. Patients were considered lost to follow-up if they had not
experienced BPAR, graft loss or death and their last contact was on Day 154
Table 1: Patient demographics and baseline characteristics
Study 1 Study 2
(without basiliximab) (with basiliximab)
Everolimus Everolimus Everolimus Everolimus
1.5 mg/day 3 mg/day 1.5 mg/day 3 mg/day
(n = 112) (n = 125) (n = 117) (n = 139)
Mean age ± SD 42.5 ± 12.3 42.8 ± 12.8 43.9 ±12.7 46.3 ± 11.8
(years) [range] [19–67] [19–67] [18–68] [19–71]
Gender (% male) 70 (62.5%) 67 (53.6%) 81 (69.2%) 87 (62.6%)
Ethnicity
Caucasian 88 (78.6%) 83 (66.4%) 106 (90.6%) 116 (83.5%)
Black 0 15 (12.0%) 0 13 (9.4%)
Hispanic 13 (11.6%) 14 (11.2%) 4 (3.4%) 4 (2.9%)
Oriental 0 5 (4.0%) 4 (3.4%) 3 (2.2%)
Other 11 (9.8%) 8 (6.4%) 3 (2.6%) 3 (2.2%)
BMI 24.2 ± 4.1 25.0 ± 4.7 25.3 ± 4.3 25.6 ± 5.0
Primary cause of
end-stage renal disease
Glomerular disease 30 (26.8%) 38 (30.4%) 32 (27.4%) 41 (29.5%)
Polycystic disease 16 (14.3%) 15 (12.0%) 14 (12.0%) 23 (16.5%)
Hypertension/ 12 (10.7%) 21 (16.8%) 4 (3.4%) 12 (8.6%)
nephrosclerosis
Diabetes mellitus 6 (5.4%) 7 (5.6%) 10 (8.5%) 15 (10.8%)
Unknown 24 (21.4%) 19 (15.2%) 19 (16.2%) 10 (7.2%)
Other 13 (11.6%) 15 (12.0%) 24 (20.5%) 22 (15.8%)
Cadaveric donor 67 (59.8%) 82 (65.6%) 79 (67.5%) 107 (77.0%)
Patients with DGF 16 (14.3%) 21 (16.8%) 23 (19.7%) 28 (20.1%)
Mean HLA mismatches
<3 27 (24.1%) 30 (24.0%) 22 (33.8%) 14 (20.6%)
≥3 84 (75.0%) 93 (74.4%) 43 (66.2%) 53 (77.9%)
Unknown 1 (0.9%) 2 (1.6%) 0 1 (1.5%)
%Patients with 10.8 5.6 13.7 12.3
panel reactive
antibodies >10% (n = 93) (n = 106) (n = 111) (n = 133)
Mean cold ischemia
time ± SD (hours)
Cadaveric donor 16.5 ± 5.8 17.6 ± 6.2 16.4 ± 6.5 16.3 ± 6.1
Living donor 1.4 ± 1.4 1.6 ± 2.1 1.3 ± 1.0 1.3 ± 1.3
Mean donor age ± SD
(years) 42.4 ± 12.7 40.9 ± 13.9 40.6 ± 13.5 37.9 ± 14.2
DGF: delayed graft function.
or before. Comparisons between treatment groups of the proportion of pa-
tients experiencing composite efficacy failure and its individual components
were made using Fisher’s exact test. There was no p-value adjustment for
multiple analyses.
Cox regression was used to model the effect of everolimus and CsA expo-
sure on BPAR. The exposure was expressed as geometric mean until BPAR
or censoring at Day 225.
Results
This paper reports separately the 6-month results from the
two 12-month studies.
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Patient populations
All patients were included in the ITT and safety populations.
Baseline demographics and background characteristics are
shown in Table 1. There were no significant differences
between the 1.5 and 3 mg/day treatment groups in either
study, other than the inclusion of all black patients in the
3 mg/day everolimus cohorts (see Materials and Methods).
Despite a functioning graft being an inclusion criterion in
Study 1, 14% and 17% of patients in each treatment arm
had delayed graft function.
Immunosuppression
Overall mean average daily doses of everolimus, including
days without medication, were 1.8 and 2.6 mg in Study 1,
and 2.2 and 3.0 mg in Study 2, in the 1.5 and 3 mg/day
treatment groups, respectively (Table 2). The incidence of
everolimus trough levels <3 ng/mL was significantly higher
in the 1.5 mg/day group than the 3 mg/day group in both
studies at Day 7 (Study 1: 21% vs. 2%, p < 0.001; Study
2: 42% vs. 9%, p < 0.001) and at Day 14 (Study 1: 23%
vs. 6%, p < 0.001; Study 2: 34% vs. 15%, p = 0.001). At
Month 6, few patients in either the 1.5 or 3 mg/day groups
had trough concentrations of less than 3 ng/mL (Study 1:
3% and 2%; Study 2: 2% and 4%, respectively).
Overall mean average daily CsA dose was similar between
the everolimus 1.5 and 3 mg/day treatment groups within
each study (Study 1: 3.7 mg/kg vs. 3.4 mg/kg; Study 2: 2.5
mg/kg in both arms). Mean C2 decreased over time, but
were slightly above target after Week 4 in Study 1, remain-
ing above target to Month 6. In Study 2, mean C2 values
slightly exceeded target range at all time points (Table 3).
The overall mean daily dose of corticosteroids was the
same in both treatment groups in each study (0.4 mg/kg).
In Study 2, all patients received their first dose of basilix-
imab, and only four patients did not receive their second
dose (two in each group).
Renal function
Renal function was good at Month 6 in patients receiving
either everolimus 1.5 or 3 mg/day in both studies, as mea-
sured by calculated GFR or serum creatinine (Table 4). In
Table 2: Everolimus dose and trough concentrations by visit window (mean ± standard deviation)
Everolimus dose and trough concentrations
Study 1 Study 2
1.5 mg/day Everolimus 3 mg/day Everolimus 1.5 mg/day Everolimus 3 mg/day Everolimus
(n = 112) (n = 125) (n = 117) (n = 139)
Everolimus Everolimus Everolimus Everolimus Everolimus Everolimus Everolimus Everolimus
Visit dose, mg/day C0, ng/mL dose, mg/day C0, ng/mL dose, mg/day C0, ng/mL dose, mg/day C0, ng/mL
Day 28 1.8 ± 0.8 5.0 ± 2.2 2.6 ± 0.7 7.6 ± 4.4 2.2 ± 0.9 5.3 ± 2.0 3.0 ± 0.9 6.6 ± 3.2
(n = 106) (n = 102) (n = 119) (n = 113) (n = 112) (n = 109) (n = 133) (n = 128)
Month 3 1.8 ± 0.6 5.4 ± 2.8 2.5 ± 0.7 7.5 ± 3.5 2.4 ± 1.0 6.3 ± 2.5 3.0 ± 1.1 7.9 ± 3.6
(n = 96) (n = 91) (n = 107) (n = 103) (n = 105) (n = 97) (n = 125) (n = 119)
Month 6 1.8 ± 0.6 5.2 ± 1.8 2.5 ± 0.7 7.3 ± 3.0 2.4 ± 0.9 6.5 ± 3.8 3.0 ± 0.9 7.6 ± 3.2
(n = 86) (n = 82) (n = 103) (n = 98) (n = 99) (n = 97) (n = 118) (n = 118)
Study 1, median calculated GFR values were 65 mL/min
and 62 mL/min in the 1.5 and 3 mg/day groups, respec-
tively (median serum creatinine 133 and 132 lmol/L); in
Study 2 these values were 66 mL/min and 67 mL/min in
(median serum creatinine 130 lmol/L in both treatment
groups).
Serum creatinine concentration in Study 1 was ≤132
lmol/L (1.5 mg/dL) at Month 6 in 49% and 50% of patients
in the 1.5 and 3 mg/day treatment groups, respectively, and
in 53% and 58% of those in Study 2. Serum creatinine was
≤185 lmol/L (2.1 mg/dL) at Month 6 in 88% and 85% of
patients in the 1.5 and 3 mg/day treatment groups in Study
1, respectively, and in 89% and 87% of patients in Study
2 (Table 4).
Efficacy
The incidence of death or graft loss was low in all patient
groups (Table 5). Seven patients in Study 1 lost their graft
due to acute rejection (n = 2), chronic rejection (n = 1),
infection (n = 1), infarcted kidney (n = 1), renal artery
thrombosis (n = 1) or other reasons (n = 1). In Study 2,
nine grafts were lost; causes included urologic complica-
tions, acute rejection, infarcted kidney, malignancy in the
allograft, primary nonfunction, technical failure and other
reasons (sepsis and micotic aneurysm).
There were no significant differences in either study be-
tween the everolimus 1.5 and 3 mg/day groups for any
efficacy parameter (Table 5), although there was a non-
significant trend to reduced incidence of BPAR in Study 1
among patients in the 3 mg/day cohort compared with the
1.5 mg/day group (p = 0.073). Most cases of BPAR were
mild or moderate in severity; only four cases of BPAR were
Grade III in Study 1 (two in each treatment group) and
two cases in Study 2 (both in the 3 mg/day group). In the
3 mg/day groups the proportion of patients experiencing
BPAR was similar in the two studies, as was the propor-
tion of patients in whom the first episode of BPAR oc-
curred by day 14 post-transplant. In the 1.5 mg/day groups,
more patients experienced BPAR in Study 1 than Study 2
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Table 3: Cyclosporine (CsA) target C2 range and dose, trough (C0), and peak (C2) concentrations by visit window (mean ± standard
deviation)
Study 1
1.5 mg/day Everolimus (n = 112) 3 mg/day Everolimus (n = 125)
Target C2
(range), CsA dose, C2, C0, CsA dose, C2, C0,
ng/mL Visit mg/kg ng/mL ng/mL mg/kg ng/mL ng/mL
Weeks 0–4 Day 28 4.7 ± 1.7 1121.2 ± 358.7 239.0 ± 134.2 4.6 ± 1.9 1166.5 ± 410.0 278.3 ± 206.8
1200 (n = 106) (n = 103) (n = 101) (n = 119) (n = 119) (n = 110)
(1000–1400)
Weeks 5–8 Month 2 3.4 ± 1.4 902.7 ± 400.7 172.9 ± 119.0 3.3 ± 1.2 855.2 ± 347.2 176.8 ± 108.6
800 (n = 99) (n = 98) (n = 93) (n = 112) (n = 112) (n = 111)
(700–900)
Weeks 9–12 Month 3 2.8 ± 1.1 685.1 ± 283.9 131.3 ± 85.3 2.6 ± 1.0 754.1 ± 362.0 140.3 ± 99.1
600 (n = 96) (n = 95) (n = 91) (n = 107) (n = 103) (n = 101)
(550–650)
Month 4–end Month 4 2.4 ± 0.9 595.0 ± 258.3 98.9 ± 58.8 2.1 ± 0.8 582.6 ± 298.2 101.0 ± 78.6
400 (n = 91) (n = 89) (n = 84) (n = 105) (n = 102) (n = 99)
(350–450)
Month 6 2.1 ± 0.7 533.6 ± 264.8 81.7 ± 59.5 1.9 ± 0.7 544.7 ± 318.1 83.1 ± 67.0
(n = 86) (n = 84) (n = 80) (n = 103) (n = 99) (n = 96)
Study 2
1.5 mg/day Everolimus (n = 112) 3 mg/day Everolimus (n = 125)
Weeks Day 28 3.0 ± 1.0 699.0 ± 265.4 140.9 ± 127.4 3.0 ± 1.2 705.9 ± 280.5 136.4 ± 121.3
0–8 (n = 112) (n = 111) (n = 106) (n = 133) (n = 128) (n = 128)
600 Month 2 2.6 ± 0.9 648.1 ± 247.2 115.7 ± 89.7 2.6 ± 1.2 627.0 ± 276.3 120.7 ± 92.3
(500–700) (n = 110) (n = 107) (n = 105) (n = 127) (n = 124) (n = 122)
Week 9–study Month 3 2.3 ± 0.9 555.2 ± 228.8 86.7 ± 46.9 2.2 ± 1.1 557.5 ± 283.3 95.4 ± 79.3
end (n = 105) (n = 100) (n = 97) (n = 125) (n = 120) (n = 116)
400 (350–450) Month 4 2.1 ± 0.9 507.0 ± 191.4 72.3 ± 33.9 2.1 ± 0.9 506.0 ± 237.1 79.1 ± 54.5
(n = 101) (n = 100) (n = 97) (n = 121) (n = 119) (n = 116)
Month 6 2.0 ± 0.8 447.6 ± 159.6 63.7 ± 31.6 1.9 ± 0.7 459.6 ± 207.9 67.7 ± 58.9
(n = 99) (n = 96) (n = 96) (n = 118) (n = 117) (n = 115)
Table 4: Serum creatinine and calculated clearance values for everolimus at 6 months (patients with at least one assessment in any visit
window, including data obtained after discontinuation of study medication)
Study 1 Study 2
(without basiliximab) (with basiliximab)
Everolimus Everolimus Everolimus Everolimus
1.5 mg/day 3 mg/day 1.5 mg/day 3 mg/day
Median calculated 65 62 66 67
GFRa (mL/min) [63 ± 19.5] [62 ± 18.3] [66 ± 18.8] [65 ± 16.0]
[mean ± SD] (n = 102) (n = 111) (n = 107) (n = 123)
Median serum 133 132 130 130
creatinine (lmol/L) [147 ± 104.7] [140 ± 53.1] [137 ± 49.8] [136 ± 42.3]
[mean ± SD] (n = 105) (n = 112) (n = 113) (n = 127)
Number of patients 51 (49%) 56 (50%) 60 (53%) 74 (58%)
with serum creatinine (n = 105) (n = 112) (n = 113) (n = 127)
≤132 lmol/L at
6 months (%)
Number of patients 92 (88%) 95 (85%) 101 (89%) 111 (87%)
with serum creatinine (n = 105) (n = 112) (n = 113) (n = 127)
≤185 lmol/L at
6 months (%)
aCalculated by the Nankivell formula (19).
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Table 5: Efficacy-related events at 6 months (intent-to-treat analyses)
Study 1 Study 2
(without basiliximab) (with basiliximab)
Everolimus Everolimus Everolimus Everolimus
1.5 mg/day 3 mg/day 1.5 mg/day 3 mg/day
(n = 112) (n = 125) pa (n = 117) (n = 139) pa
Efficacy failureb 31 (27.7%) 24 (19.2%) 0.127 18 (15.4%) 27 (19.4%) 0.415
Biopsy-proven 28 (25.0%) 19 (15.2%) 0.073 16 (13.7%) 21 (15.1%) 0.859
acute rejection
Graft loss/death 5 (4.5%) 6 (4.8%) 1.000 2 (1.7%) 7 (5.0%) 0.187
Graft loss 5 (4.5%) 2 (1.6%) 0.260 2 (1.7%) 7 (5.0%) 0.187
Death 0 4 (3.2%) 0.124 0 1 (0.7%) 1.000
Lost to follow-up 1 (0.9%) 0 0.473 0 3 (2.2%) 0.253
aFisher’s exact test.
bBPAR, graft loss, death or lost to follow-up.
Figure 1: Incidence of biopsy-proven acute rejection (BPAR)
at 6 months among patients with an everolimus trough level
<3 ng/mL or ≥3 ng/mL; everolimus exposure calculated as
arithmetic mean until BPAR or censoring at day 225.
(Table 5), and a higher proportion of patients with BPAR in
Study 1 experienced their first episode within the first 14
days post-transplant (10/34, 29.4%) compared with Study
2 (2/17, 11.8%).
Effect of drug exposure
In both studies, BPAR was more common among pa-
tients with a mean everolimus trough concentration below
3 ng/mL compared with those with a trough concentration
of 3 ng/mL or above (Figure 1) (Study 1: 6/8 vs. 38/221,
p < 0.0001; Study 2: 3/6 vs. 31/246, p < 0.05). A Cox regres-
sion model demonstrated that risk of BPAR was affected by
everolimus exposure; this relationship approached signifi-
cance in Study 1 (p = 0.054) and was significant in Study 2
(p = 0.001). In patients with an everolimus trough concen-
tration <3 ng/mL, use of basiliximab appeared to reduce
the risk of BPAR: 6/8 patients with trough concentration
<3 ng/mL in Study 1 experienced BPAR compared with
3/6 in Study 2. For patients with a trough concentration >3
ng/mL, addition of basiliximab had a less marked effect on
risk of BPAR (Figure 1).
Discontinuations
At the 6-month analysis in Study 1, the incidence of dis-
continuation of study medication was higher in the 1.5 mg
group compared with the 3 mg group. In Study 2, the inci-
dence was similar in both groups. The most common rea-
son for discontinuation of study medication in both stud-
ies was adverse events (Table 6). The only adverse event
leading to discontinuation of study medication reported by
greater than two patients was arthralgia in the Study 1
1.5 mg group. One patient in the 1.5 mg group in both
studies discontinued due to thrombocytopenia, and 1 pa-
tient in the 3 mg group of Study 2 discontinued due to
hyperlipidemia.
Safety
Almost all patients experienced adverse events (Table 7),
with no significant between-group differences relating
to the incidence or type of adverse events reported in
either study. Infection was common, occurring in 50–
60% of patients, with urinary tract infections being the
most frequently reported, and with a low incidence of
cytomegalovirus infection. The most frequent hemato-
logic adverse event was anemia, with low incidences of
leukopenia and thrombocytopenia. Neutropenia occurred
in one patient receiving 1.5 mg/day in each study, and in
three and two patients in the 3 mg/day group in Studies
1 and 2, respectively. At 6 months, in Study 1, values for
mean hemoglobin, white blood cells (WBC), and platelets
were 8.3 mmol/L, 8.0 × 109/L, and 244 × 109/L, respec-
tively, in the 1.5 mg/day group and 8.1 mmol/L, 7.4 × 109/L,
and 228 × 109/L in the 3 mg/day group. The corresponding
values in Study 2 were 7.9 mmol/L, 7.4 × 109/L, and 240 ×
109/L in the 1.5 mg/day group and 7.8 mmol/L, 7.0 × 109/L,
and 246 × 109/L in the 3 mg/day group.
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Table 6: Patient disposition (intent-to-treat population)
Study 1 Study 2
(without basiliximab) (with basiliximab)
Everolimus Everolimus Everolimus Everolimus
1.5 mg/day 3 mg/day 1.5 mg/day 3 mg/day
(n = 112) (n = 125) (n = 117) (n = 139)
Discontinued study 30 (26.8%) 25 (20.0%) 22 (18.8%) 22 (15.8%)
medication
Adverse event 21 (18.8%) 13 (10.4%) 14 (12.0%) 13 (9.4%)
Abnormal laboratory 1 (0.9%) 1 (0.8%) 2 (1.7%) 0
value (s)
Unsatisfactory 3 (2.7%) 4 (3.2%) 3 (2.6%) 4 (2.9%)
therapeutic effect
Protocol violation 2 (1.8%) 0 1 (0.9%) 0
Withdrew consent 0 2 (1.6%) 0 2 (1.4%)
Death 0 3 (2.4%) 0 0
Graft loss 3 (2.7%) 2 (1.6%) 2 (1.7%) 3 (2.2%)
Still in study 111 (99.1%) 120 (96.0%) 116 (99.1%) 136 (97.8%)
The incidence of new-onset diabetes after transplantation
was 4% in the 1.5 mg/day group and 5% in the 3 mg/day
group in Study 1, and 4% and 3%, respectively, in Study 2.
The incidence of major adverse cardiac events was low in
both studies (3% in both cohorts in Study 1, 2% in both
groups in Study 2). Hemolytic uremic syndrome was re-
ported in three patients receiving 1.5 mg/day everolimus
and one receiving 3 mg/day in each study.
In Study 1, mean total cholesterol concentration increased
from 4.2 and 3.9 mmol/L at baseline to 6.6 and 6.5 mmol/L
at Month 6 for the 1.5 mg/day and 3 mg/day cohorts,
respectively. For patients in Study 2, the baseline value
was 4.3 mmol/L in both cohorts, rising to 6.2 mmol/L and
6.1 mmol/L for the 1.5 and 3 mg/day groups, respectively.
The pattern of increase in triglyceride levels was similar.
Generally, increases in either total cholesterol or triglyc-
erides were apparent by Month 2–3, after which they sta-
bilized. Lipid-lowering agents, mostly statins, were used
in 58.9% and 66.4% of patients in Study 1, and in 66.7%
and 72.7% of patients in Study 2 receiving 1.5 or 3 mg/day,
respectively.
Discussion
Previous strategies to exploit the synergistic effect of
proliferation signal inhibitors and CsA have resulted in an
imbalance between immunosuppressive efficacy and renal
safety. Early trials, in which fixed-dose sirolimus was used
in combination with full-dose CsA, reported low incidences
of acute rejection but at the cost of impaired renal function
(22–24), a finding that resulted from potentiation of CsA
nephrotoxicity by sirolimus (25). Subsequently, early with-
drawal of CsA with a maintenance regimen of sirolimus
and steroids has been attempted, resulting in improved re-
nal function but with a significantly higher risk of late acute
rejection (26), which is known to be a predictor of chronic
rejection (27) and graft loss (28). Moreover, the relatively
high dose of sirolimus necessitated by CsA withdrawal led
to an increase in sirolimus-related adverse events (26). Al-
though everolimus does not increase CsA levels, similar
renal findings were found using everolimus with full-dose
CsA in Phase III trials (11,12,29).
In the two studies described here, C2 adjusted dosing
of CsA levels was used to achieve exposure lower than
those in earlier studies of everolimus and full-dose CsA
(11,12). After Month 1, the CsA C2 level in Study 1
was approximately a third lower than typically targeted
(30), and corresponding trough CsA levels were approx-
imately half those seen in studies of everolimus with
full-dose CsA (11,12). In Study 2, target C2 levels were
approximately half that typically used (30); trough levels
were a little over a third of those reported in patients re-
ceiving everolimus with full-dose CsA (11,12). Low CNI
exposure may be associated with long-term clinical ben-
efits, such as reduced risk of chronic renal allograft
dysfunction (31), hypertension or new-onset diabetes after
transplantation (32), which in turn could contribute to im-
proved patient and graft survival. Concentration-controlled
everolimus with low-exposure CsA has the potential to
minimize chronic CNI-related toxicity. Further data are re-
quired to assess the clinical effect of low-exposure CsA
within this regimen over the longer term.
The studies presented here demonstrate that optimiz-
ing drug exposure for both everolimus and CsA achieves
an effective balance of immunosuppression and renal
function. Concentration-controlled everolimus and low-
exposure CsA was effective in preventing graft rejection,
while the effects on renal function were similar to those
reported with current regimens (30,33,34). The optimized
everolimus/CsA regimens appeared to be associated with
better preservation of renal function than comparable high-
exposure CsA regimens in Phase II and III everolimus
trials (11–13). Addition of the IL-2 antagonist basiliximab
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Table 7: Number (%) of patients reporting common adverse events (AEs) by 6 months (safety analyses)
Study 1 Study 2
(without basiliximab) (with basiliximab)
Everolimus Everolimus Everolimus Everolimus
1.5 mg/day 3 mg/day 1.5 mg/day 3 mg/day
(n = 112) (n = 125) (n = 117) (n = 139)
Any AE/infection 111 (99.1%) 123 (98.4%) 116 (99.1%) 139 (100%)
Any infection 69 (61.6%) 71 (56.8%) 68 (58.1%) 76 (54.7%)
Urinary tract 32 (28.6%) 34 (27.2%) 25 (21.4%) 30 (21.6%)
CMV 1 (0.9%) 4 (3.2%) 3 (2.6%) 3 (2.2%)
Herpes simplex 8 (7.1%) 1 (0.8%) 4 (3.4%) 11 (7.9%)
Pneumonia 4 (3.6%) 5 (4.0%) 2 (1.7%) 4 (2.9%)
Upper respiratory tract 5 (4.5%) 1 (0.8%) 9 (7.7%) 11 (7.9%)
Infection reported 17 (15.2%) 22 (17.6%) 20 (17.1%) 19 (13.7%)
as serious AE
Malignancy 1 (0.9%) 2 (1.6%) 1 (0.9%) 2 (1.4%)
Blood and lymphatic 41 (36.6%) 50 (40.0%) 40 (34.2%) 64 (46.0%)
system disorders
Anemia NOS 21 (18.8%) 28 (22.4%) 28 (23.9%) 41 (29.5%)
Leukopenia 5 (4.5%) 5 (4.0%) 4 (3.4%) 14 (10.1%)
Thrombocytopenia 4 (3.6%) 10 (8.0%) 4 (3.4%) 8 (5.8%)
Cardiac disorders 18 (16.1%) 22 (17.6%) 10 (8.5%) 19 (13.7%)
Hypertension NOS 17 (15.2%) 25 (20.0%) 30 (25.6%) 35 (25.2%)
Lymphocele 17 (15.2%) 8 (6.4%) 12 (10.3%) 10 (7.2%)
Gastrointestinal 68 (60.7%) 73 (58.4%) 57 (48.7%) 83 (59.7%)
disorders
Constipation 26 (23.2%) 32 (25.6%) 32 (27.4%) 42 (30.2%)
Diarrhea NOS 18 (16.1%) 10 (8.0%) 15 (12.8%) 18 (12.9%)
Total cholesterol 93 (83.0%) 105 (84.0%) 94 (81.0%) 122 (87.8%)
≥6.2 mmol/L
(239 mg/dL)
Total cholesterol 25 (22.3%) 31 (24.8%) 22 (19.0%) 29 (20.9%)
≥9.1 mmol/L
(351 mg/dL)
Triglycerides 33 (29.5%) 57 (45.6%) 48 (41.4%) 53 (38.1%)
≥4.5 mmol/L
(398 mg/dL)
Triglycerides 4 (3.6%) 10 (8.0%) 6 (5.2%) 11 (7.9%)
≥8.5 mmol/L
(752 mg/dL)
Blood glucose 12 (10.7%) 13 (10.4%) 10 (8.6%) 12 (8.6%)
>13.9 mmol/L
(250 mg/dL)
Respiratory, thoracic 38 (33.9%) 39 (31.2%) 30 (25.6%) 31 (22.3%)
and mediastinal disorders
Cough 11 (9.8%) 8 (6.4%) 3 (2.6%) 2 (1.4%)
Nasopharyngitis 8 (7.1%) 6 (4.8%) 2 (1.7%) 6 (4.3%)
Skin and 32 (28.6%) 39 (31.2%) 25 (21.4%) 30 (21.6%)
subcutaneous
disorders
Acne NOS 9 (8.0%) 11 (8.8%) 12 (10.3%) 9 (6.5%)
CMV: cytomegalovirus; NOS: not otherwise specified.
decreased the incidence of acute rejection among those
who did not achieve a therapeutic level of everolimus ex-
posure (3 ng/mL).
Hariharan and colleagues (2) have reported that 6-
month serum creatinine >132 mmol/L (1.5 mg/dL) is
associated with a decline in long-term graft function.
Overall, in the studies reported here, over 50% of patients
had a 6-month creatinine value ≤132 mmol/L, indicating ex-
cellent long-term graft prognosis. Creatinine values >185
mmol/L (2.1 mg/dL) are associated with less than half the
projected graft half-life calculated for those with excellent
renal function (2); less then 15% of patients in these stud-
ies had values >185 mmol/L.
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In terms of efficacy, 6-month rejection rates in Study 1
were similar in the 3 mg/day arm to those seen with higher
C2 levels in combination with MMF or azathioprine and
steroids (30). Overall, the incidence of efficacy failure com-
pares favorably with that previously reported in multicen-
ter efficacy trials. The incidence of rejection was higher
with 1.5 mg/day (25%) in Study 1, but only slightly above
that reported recently with full-dose tacrolimus-based triple
therapy (20%) (33). When basiliximab was used in addition
to everolimus and low-exposure CsA (Study 2), rejection
rates were similar to those previously reported with full-
dose CsA, MMF, steroids and basiliximab (35).
A comparison of results in the 1.5 and 3 mg/day cohorts
showed no significant differences in efficacy between
treatment groups within each trial. Safety differed only by
a numerical trend towards increased prevalence of hema-
tologic disturbances in the 3 mg/day groups. There was
a higher incidence of rejection in the 1.5 mg/day group in
Study 1. Although there was considerable overlap between
patients in the different treatment groups in terms of
everolimus trough levels, more patients in the 1.5 mg/day
group fell below the minimum level of 3 ng/mL, which may
account for the higher rate of rejection in this cohort. A min-
imum everolimus trough level of 3 ng/mL was selected on
the basis of a retrospective analysis of data from a Phase III
trial of everolimus which showed a strong relationship
between an everolimus trough level >3 ng/mL and
prevention of acute rejection, regardless of CsA expo-
sure (15). Results presented here also indicate that an
everolimus trough level >3 ng/mL is associated with a re-
duced risk of rejection. Few acute rejections occurred after
month 3. Thus, therapeutic drug monitoring of everolimus
can enhance both efficacy and safety of the regimen by
allowing initial use of 1.5 mg/day with dose increments
as required to ensure a trough concentration of at least 3
ng/mL. Black patients, in whom CsA and everolimus clear-
ance rate is higher than nonblacks (14), still experienced a
rate of acute rejection higher than nonBlacks, suggesting
caution must still be observed in monitoring everolimus
and CsA levels.
In conclusion, concentration-controlled everolimus in
combination with low-exposure CsA results in effective
protection against rejection with good renal function. Ther-
apeutic drug monitoring to optimize exposure to both
everolimus and CsA offers an innovative strategy that al-
lows individualization of immunosuppression after trans-
plantation. Long-term data are required to determine
whether use of this regimen also helps to reduce risk of
chronic allograft nephropathy.
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